Sylvia Herter

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 929 citations · Full text

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

Tilman Schlothauer, Sylvia Herter, Claudia Ferrara et al. · Protein Engineering Design and Selection · 2016 · 388 citations · Full text

Immunology, Immune Regulation, Immunodominance +24

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl et al. · Molecular Cancer Therapeutics · 2013 · 352 citations

Xenograft Models, Immunology, Immune Regulation +20

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus, Claudia Ferrara, Wei Xu et al. · Science Translational Medicine · 2019 · 252 citations · Full text

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto et al. · Nature · 2022 · 238 citations · Full text